These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 37909437)
1. Biological Significance of EphB4 Expression in Cancer. Ullah A; Razzaq A; Zhou C; Ullah N; Shehzadi S; Aziz T; Alfaifi MY; Elbehairi SEI; Iqbal H Curr Protein Pept Sci; 2024; 25(3):244-255. PubMed ID: 37909437 [TBL] [Abstract][Full Text] [Related]
2. Targeting receptor tyrosine kinase EphB4 in cancer therapy. Chen Y; Zhang H; Zhang Y Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206 [TBL] [Abstract][Full Text] [Related]
3. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor. Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627 [TBL] [Abstract][Full Text] [Related]
4. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Kuang SQ; Bai H; Fang ZH; Lopez G; Yang H; Tong W; Wang ZZ; Garcia-Manero G Blood; 2010 Mar; 115(12):2412-9. PubMed ID: 20061560 [TBL] [Abstract][Full Text] [Related]
5. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4. Duggineni S; Mitra S; Noberini R; Han X; Lin N; Xu Y; Tian W; An J; Pasquale EB; Huang Z Biochem Pharmacol; 2013 Feb; 85(4):507-13. PubMed ID: 23253822 [TBL] [Abstract][Full Text] [Related]
7. Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers. Liersch-Löhn B; Slavova N; Buhr HJ; Bennani-Baiti IM Int J Cancer; 2016 Mar; 138(5):1220-31. PubMed ID: 26414866 [TBL] [Abstract][Full Text] [Related]
8. EphrinB2-EphB4 Signaling in Neurooncological Disease. Piffko A; Uhl C; Vajkoczy P; Czabanka M; Broggini T Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163601 [TBL] [Abstract][Full Text] [Related]
9. Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers. Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T Gynecol Oncol; 2009 Jul; 114(1):84-8. PubMed ID: 19356789 [TBL] [Abstract][Full Text] [Related]
10. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease. Piffko A; Broggini T; Harms C; Adams RH; Vajkoczy P; Czabanka M Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360793 [TBL] [Abstract][Full Text] [Related]
11. Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer. Takai N; Miyazaki T; Fujisawa K; Nasu K; Miyakawa I Oncol Rep; 2001; 8(3):567-73. PubMed ID: 11295082 [TBL] [Abstract][Full Text] [Related]
12. Expression of Ephb2 and Ephb4 in breast carcinoma. Wu Q; Suo Z; Risberg B; Karlsson MG; Villman K; Nesland JM Pathol Oncol Res; 2004; 10(1):26-33. PubMed ID: 15029258 [TBL] [Abstract][Full Text] [Related]
13. Distribution of EphB4 and EphrinB2 in normal and malignant urogenital tissue. Ozgür E; Heidenreich A; Dagtekin O; Engelmann U; Bloch W Urol Oncol; 2011; 29(1):78-84. PubMed ID: 19272799 [TBL] [Abstract][Full Text] [Related]
14. Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy. Zamora DO; Davies MH; Planck SR; Rosenbaum JT; Powers MR Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2175-82. PubMed ID: 15914639 [TBL] [Abstract][Full Text] [Related]
15. EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target. Xiao Z; Carrasco R; Kinneer K; Sabol D; Jallal B; Coats S; Tice DA Cancer Biol Ther; 2012 Jun; 13(8):630-7. PubMed ID: 22555806 [TBL] [Abstract][Full Text] [Related]
16. Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts. Kwan Tat S; Pelletier JP; Amiable N; Boileau C; Lajeunesse D; Duval N; Martel-Pelletier J Arthritis Rheum; 2008 Dec; 58(12):3820-30. PubMed ID: 19035475 [TBL] [Abstract][Full Text] [Related]
17. A narrative review of the role of Eph receptors in head and neck squamous cell carcinoma. Al-Jamaei AAH; Subramanyam RV; Helder MN; Forouzanfar T; van der Meij EH; Al-Jamei S; de Visscher JGAM Oral Dis; 2024 Apr; 30(3):833-845. PubMed ID: 37279081 [TBL] [Abstract][Full Text] [Related]
18. EphrinB2 and EphB4 expression in pterygia: new insights and preliminary results. Xue C; Huang Z; Wang J; Dong Y; Zhou X Can J Ophthalmol; 2009 Apr; 44(2):185-8. PubMed ID: 19491953 [TBL] [Abstract][Full Text] [Related]
19. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand. Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689 [TBL] [Abstract][Full Text] [Related]
20. Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands. Falivelli G; Lisabeth EM; Rubio de la Torre E; Perez-Tenorio G; Tosato G; Salvucci O; Pasquale EB PLoS One; 2013; 8(11):e81445. PubMed ID: 24348920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]